From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) convened in San Diego, bringing together leading experts to discuss pivotal advances in hematology. Among the highlights was a groundbreaking study by Dr. Shanshan Pei and his team from The First Affiliated Hospital,Zhejiang University and Liangzhu Laboratory. This study (Abstract #38), selected for oral presentation, identified the rare fusion gene TFG-ROS1 as an oncogenic driver in human myeloid leukemia. Furthermore, the team demonstrated effective treatment strategies using ALK/ROS1 inhibitors, achieving remission in a patient with refractory leukemia after multiple treatment failures. This study exemplifies the “bench-to-bedside” paradigm in precision medicine, showcasing its transformative potential for cancer care. Below is an in-depth exploration of the study and exclusive insights from Professor Pei.

From December 7 to 10, 2024, the 66th Annual Meeting of the American Society of Hematology (ASH) was held in San Diego, USA. Experts and scholars from around the globe gathered to discuss and exchange insights on the latest research in hematology. During the conference, Dr. Bing Han from Peking Union Medical College provided an on-site review of two significant studies from the Severe Aplastic Anemia Working Party (EBMT-SAAWP) of the European Society for Blood and Marrow Transplantation. Professor Han also shared in-depth analyses of key research topics presented at the meeting. These highlights are summarized below for our readers.